Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

More Patient Deaths Put Hold on Juno’s CAR-T Immunotherapy Clinical Trial

XTALKS VITALS NEWS

CAR-T

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events.

Share this!

November 29, 2016 | by Sarah Hand, M.Sc.

Biopharmaceutical company Juno Therapeutics, has announced that more patients participating in their CAR-T immunotherapy clinical trial, have died as a result of the treatment. Two patients suffered severe cerebral edema – swelling of the brain – which led to the death of one patient, and the prediction that the other will not recover.

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events. Just a few months ago, three patients with relapsed or refractory B cell acute lymphoblastic leukemia died during the course of the study, prompting the US Food and Drug Administration (FDA) to enforce a temporary clinical hold while the deaths were investigated.

Juno quickly identified a specific chemotherapy drug, fludarabine, as the cause of the patient deaths, which was used as a pre-conditioning treatment before the CAR-T cell therapy was administered. However, even after removing this drug from the study protocol after resuming the trial, the ROCKET trial has still been plagued by more patient deaths.

It is our view that the removal of fludarabine has reduced the incidence of severe neurotoxicity,” said Hans Bishop, CEO of Juno Therapeutics in a conference call regarding the trial last week. “It just hasn’t gotten us as far as we hoped that it would.”



Now that five patient deaths have been associated with the CAR-T immunotherapy trial, Juno is sure to face many questions regarding the safety of JCAR015. As the FDA was the one to allow the clinical trial to continue following the first deaths, the regulatory agency will likely face increased scrutiny over the coming weeks.

“It’s just terrible,” Brad Loncar, founder of a cancer immunotherapy fund, told Stat News. “They’ve killed a couple of people, and it seems like, in part, it’s because of the rush to judgment.”

According to Bishop, the patients participating in the ROCKET trial were already suffering the effects of the rare, but highly-lethal form of blood cancer before joining the study. As Juno still has other CAR-T clinical trials on the go, they could still meet their target of launching their first therapeutic by 2018.


Keywords: CAR-T, Immunotherapy, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.